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Abstract 
Institutional Review Boards (IRBs) are a critical component of clinical research and can become 
a significant bottleneck due to the dramatic increase, in both volume and complexity of clinical 
research. Despite the interest in developing clinical research informatics (CRI) systems and 
supporting data standards to increase clinical research efficiency and interoperability, informatics 
research in the IRB domain has not attracted much attention in the scientific community. The 
lack of standardized and structured application forms across different IRBs causes inefficient and 
inconsistent proposal reviews and cumbersome workflows. These issues are even more 
prominent in multi-institutional clinical research that is rapidly becoming the norm. This paper 
proposes and evaluates a domain analysis model for electronic IRB (eIRB) systems, paving the 
way for streamlined clinical research workflow via integration with other CRI systems and 
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1. Introduction 
Remarkable growth has occurred in biomedical research in recent years [1]. The sheer amount of 
research now being conducted has resulted in an unprecedented increase in workload and placed 
a severe burden on Institutional Review Boards (IRBs
1
) [2]. In addition, in recent years there has 
been a growing trend towards multisite clinical research, complicating the effectiveness of an 
institutionally-based oversight system [3,4]. Moreover, biomedical research enabled by new 
technologies in healthcare such as retrospective cohort research involving secondary use of 
patient data from electronic health record (EHR) systems and genetic research involving 
specimens from biobanks have raised new ethical questions and concerns [5,6] that require 
additional review resources. 
IRBs are charged with reviewing of all research projects that involve humans to ensure that they 
comply with local, state, and federal laws, as well as with the ethical standards set forth by local 
policy. An IRB serves its own research community by applying high standards of intellectual 
integrity and careful attention to federal research regulations. They strive to provide investigators 
and study teams the support and resources they need to conduct high quality research and foster 
research practices that protect participants. The nature this mandate is complex, we provide 
several examples throughout this paper of specific IRB activities. 
 As the volume of research grows, the number of IRBs also increased substantially. Catania et al.  
showed that the number of U.S. IRBs increased by 41% from 2004 to 2008 [2]. According to the 
March 2013 data from the Office for Human Research Protections (OHRP), there are 2,937 
actively registered U.S. IRB organizations (IORGs) and 1,983 non-U.S. IORGs, which include 
3,589 individual U.S. IRBs and 2,252 non-U.S. IRBs, respectively [7]. 
                                                 
1
 “IRB" is a generic term used by U.S. Department of Health and Human Services to refer to a group whose function is to review 
research to assure the protection of the rights and welfare of the human subjects. Each institution may use different names such as 
Research Ethics Committee, Committee on Human Studies, the Committee on Clinical Investigations, etc. For the sake of 
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There is a substantial literature discussing the problems faced by IRBs, including redundancy of 
duplicative review for multisite studies, inconsistency in decision-making across different IRBs, 
and inefficiency in communication among different stakeholders [8–11]. Studies show that 
investigators complain that the IRB application process is burdensome and, in some instances, 
waiting to obtain IRB approval has delayed project initiation substantially [8,12]. Despite the 
increasing interest by the informatics community in developing clinical research informatics 
(CRI) systems [13,14] and its long-standing interest in data standards for system interoperability 
and data sharing [15], informatics research in the IRB domain has not attracted much attention.  
Consequentially the IRB review process is largely manual, using electronic systems primarily for 
communication. These systems are often built on simple databases that facilitate the transfer of 
non-computable electronic documents.  This point was confirmed by our analysis of IRB 
application systems at all Clinical and Translational Science Award (CTSA) centers [16]. We 
found that 72% of CTSA institutions used some form of online IRB application systems during 
the study year (2012). However, the capability of these online systems varies greatly across 
organizations. Some systems simply allow investigators to upload application-related documents 
in Word or PDF format, while others have a “smart form” feature that can dynamically guide 
investigators through relevant online forms. Even for those systems that support forms entry, the 
preponderance of fields are free-text. The unstructured information in those fields is difficult to 
process for automated analysis or for data sharing between CRI applications. 
In this paper, we propose and evaluate a domain analysis model to standardize the information 
elements within the IRB oversight domain. There have been many efforts to model various 
aspects of biomedical research in general. For example, the Protocol Representation Model 
(PRM) from the Clinical Data Interchange Standards Consortium (CDISC) [17] focuses on the 
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Biomedical Research Integrated Domain Group (BRIDG) project [18] developed a 
comprehensive domain analysis model for protocol driven research and its associated regulatory 
artifacts. The regulatory subdomain of BRIDG was designed for the Food and Drug 
Administration’s (FDA) regulated product submission process instead of IRB oversight. As a 
result it is too coarse-grained for computers to process by modeling the IRB submissions at the 
document level. The Ontology of Clinical Research (OCRe) is a formal ontology for annotating 
existing human studies and supporting federated query on data and meta-data across studies from 
different sources [19]. It focuses on the design and analysis phase of studies. To the best of our 
knowledge, however, there is no existing research on modeling the IRB oversight domain.  
The goals of the work presented here are: 1) to develop a platform-independent domain analysis 
model that captures the structured data elements and high-level business processes for the IRB 
oversight domain; and  2) to evaluate the model’s  ability to represent the informational elements 
found in five different types of real-world IRB systems. The paper presents a detailed discussion 
of the domain analysis process, the resulting IRB model, and the results of the evaluation. 
2. Model Development 
Our design strategy was to capture all essential information that IRBs require to provide human 
subjects research oversight, as well as capture information that could be meaningfully shared 
with other CRI systems. Such information is represented in a structured way when possible, 
serving as the foundation for future decision support based on predefined rules or through 
binding to an ontology. For example, if a planned study activities involve high-risk procedures 
such as ionizing radiation or informational risk such as secondary use of existing data or 
specimens, commensurate review procedures for specific risks could be suggested automatically.  
We try to avoid modeling verbatim concepts defined in regulations unless they have an extension 
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guidelines [21] by naming a list of vulnerable subject categories). We do not model entities that 
are primarily for human understanding (as opposed to computer interpretation), such as the 
standard language used in an informed consent. It may be possible in the future to facilitate 
automatic informed consent generation as a more advanced application of our model, however. 
Our intention is not to replace human review with a computer system, but to make the reviewer’s 
job easier by utilizing information collected in a machine-understandable way and presenting the 
information to the reviewers in a consistent manner. In this way, we are trying to maximize the 
advantages of both human (IRB reviewers) and automated processes, while adding the capability 
to integrate IRB systems into other CRI applications. 
The IRB domain analysis model (DAM) is an implementation-independent model built on a high 
level of abstraction of the IRB domain. A host of documented domain analysis methods are 
available from the software engineering field, but no one standard domain analysis process is 
considered "best"[22]. We adapted the Feature-Oriented Domain Analysis (FODA) method [23] 
and the conceptual modeling method presented by Embley et al. [24] for our work. Figure 1 
illustrates the IRB domain analysis process and the corresponding model artifacts generated by 
each step (i.e., context analysis, domain modeling, and business process modeling), which we 
describe in Sections 2.1-2.3. 
2.1 Context Analysis  
The first phase, context analysis, defines the scope of the modeling domain. The relationships 
between the candidate domain and its parent domain, subdomains, and peer domains are shown 
in Figure 2. The context analysis was based on careful review of federal regulations that define 
the IRB oversight scope and responsibility [25]. We found significant overlap within the IRB 
and the study protocol domain. The study protocol is the blueprint of every research project. It 
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recruitment, planned study procedures and interactions, data management, and analysis plans. 
The study protocol is essential in order for IRBs to evaluate the potential benefits and risks of a 
study. However, some details in the study protocol that may be important for study management 
purpose are not relevant for IRB review (e.g., the coding systems used for recording study 
condition and adverse events, the technique used for reporting study subject accrual data to the 
study sponsor, study acronyms, etc.). There are also certain aspects of a study that might not be 
covered in the study protocol but that are important for IRBs to know for review such as the 
informed consent process, compensation to subjects, vulnerable population participants, status 
report, unanticipated problem report, etc. Context analysis is the basis for planning the domain 
modeling phase during which all relevant entities are identified. 
 
 Figure 1. Overview of the IRB Domain Analysis Process. The IRB domain analysis process 
consists of three phases: context analysis, domain modeling and interaction architecture 
modeling. The white document-shaped boxes are the deliverables associated with each phase. 
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Figure 2. Context Analysis for the IRB Oversight Domain. This defines the scope of the 
modeling domain. Analysis of the relationship between the candidate domain and its parent 
domain, subdomains, and peer domains is useful to identify which data elements can be 
consolidated from existing standards and which should be defined. 
 
2.2 Domain Modeling 
The second phase, domain modeling, consists of entity-relationship modeling, which details the 
static (structural) semantics of the domain, as well as business process modeling, which 
illustrates the dynamic (behavioral) semantics of the domain. 
2.2.1 Domain Modeling Process 
The static artifact produced from entity-relationship modeling is called the entity-relationship 
model, which is independent of the underlying database design. Some literature refers to this as 
an information model or logical data model [26]. In this paper, these terms will be used 
interchangeably. Terminology binding connects the entity-relationship model with domain 
vocabulary specifications to standardize the terminology that describes the domain. In this paper, 
only a preliminary terminology binding effort was conducted – a comprehensive domain 
vocabulary development is considered as future work. The dynamic artifacts produced in the 
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These include the high-level, generic IRB application and review processes, augmented by a 
state machine that describes the status transition of an IRB application. This paper only discusses 
the development process for the IRB entity-relationship model (Figure 3) in detail since it is the 
basis for supporting any internal or external automated tasks and since it comprises the most 
important artifact in the IRB DAM.  
 
Figure 3 Overview of the Entity-relationship Modeling Process. This is an iterative process. 
Feedback from domain experts led us to revisit the knowledge sources and revise the draft model.  
 
First, all the key entities in the IRB oversight domain were extracted from regulation-based 
guidelines, primarily the AAHRPP (Association for the Accreditation of Human Research 
Protection Programs, Inc.) accreditation standards, with OHRP, FDA regulatory guidance 
documents and HIPAA educational materials as complementary knowledge sources. AAHRPP is 
an independent, nonprofit organization that accredits high-quality human research protection 
programs. It has published a series of accreditation standards that are compliant with U.S. federal 
regulations and international ethical principles. Specifically, the Evaluation Instrument for 
Accreditation (Version January, 2012)[27], and IRB Evaluation Checklist (Version December, 
2010) [28] were used as guidelines in the IRB domain modeling process. Each entity in the 
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HL7 Version 3 Data Type Abstract Specification (Release 2) [29]. There are too many entities to 
list here, but the complete model is available online as described below. In the online version of 
the model, entities from different knowledge sources are distinguished by different colors as 
explained by the diagram legend.  
Second, relevant entities and their attributes from the BRIDG model were used wherever 
possible, especially when the regulation guidelines did not provide sufficient detail. For example, 
AAHRPP does not define what a “full protocol” includes. In such cases, the study protocol-
related classes from BRIDG were used. However, BRIDG focuses primarily on modeling 
clinical trials (either interventional or observational) and it is missing the category of 
retrospective studies, which use existing health data for secondary analysis. We reorganized and 
modified some entities and attributes in the BRIDG model to accommodate retrospective studies 
or social/behavioral science studies. 
Third, a draft version of the IRB entity-relationship model developed from the first two steps was 
reviewed by two domain experts (a former IRB Chair and the Associate Director of the 
University of Utah IRB) to determine model accuracy. Not all entities or attributes about study 
protocol in the BRIDG model proved interesting to the IRB. Such information elements were 
eliminated from the IRB model during the expert review. To make the model more 
understandable to these domain experts, a concept map was derived from the IRB class diagram 
as a review aid. The concept map includes only the entities in the domain, and their relationships, 
without further details about as attributes or data types. It shows the big picture of the IRB 
domain and is visually simpler to comprehend than the UML class diagram. Both domain experts 
independently marked each class and associated attributes as “yes” meaning “to include” or “no” 
meaning “not to include.” After the independent reviews from each expert were completed, the 
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The final step was to evaluate the comprehensiveness of the model by comparison with real-
world IRB application systems. We mapped the online or Word/PDF forms from five large IRBs 
to the model. The evaluation results comprised of complicated mapping categories shows overall 
agreement between a real system and our model but also provided insights into future 
improvements to both model development and IRB application form design. We incorporated 
entities that were identified as missing from the evaluation process to the model. The details of 
this model evaluation will be discussed in Section 3. 
2.2.2 Domain Modeling Results 
2.2.2.1 The IRB Entity-relationship Model 
The IRB DAM is represented in Unified Modeling Language (UML) and was developed using 
Enterprise Architect (Version 9.2). The IRB entity-relationship model comprises 97 entities and 
132 relationships in total. It covers eight core areas of the IRB domain, which are illustrated over 
the concept map for display purposes only (Figure 4). The complete model in UML class 
diagram can be accessed online at http://irb-dam.bmi.utah.edu. 
The Study Protocol core represents the informational entities that pertain to the plan of a human 
subject research project. A classification of study protocols is needed because different study 
types need different information elements to describe the study. For example, a retrospective 
study uses only existing health data and does not require recruiting or interventional procedure 
plans in the study protocol. In contrast, a prospective study protocol should describe in detail the 
recruitment process and all observational or interventional procedures that will be applied to 
study participants. A well-designed study protocol typology, with relevant information elements 
defined for each study type, can facilitate “smart” form design in eIRB systems so that 
investigators do not need to answer non-applicable questions. We developed a study protocol 
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Figure 4. An Overview of the Concept Map for the IRB Oversight Domain. This diagram 
illustrates the eight core areas of the IRB domain over the concept map for display purposes 
only. It is not intended to show the individual entities and relationships in detail. To view that 




Figure 5. The Study Protocol Typology for the IRB Oversight Domain. This classification is 
designed especially for IRB review purpose. Each child study protocol type has its own 
characteristics that differentiate it from its parent. More specific study design types will be 
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The Planned Administrative Study Activity core represents those activities that are not directly 
related to the analysis of study outcomes such as participant recruitment procedures, 
compensation to study participants, and informed consent processes, etc. Since these 
administrative activities can raise significant ethical concerns, IRBs always require investigators 
to specify the details of these activities. 
The PHI Authorization core covers the informational entities that are related to the IRB (or 
Privacy Board) as regulated by the HIPAA Privacy Rule. For example, the request for waiver or 
alteration of authorization describes the PHI data elements to access, as well as the justification 
of such access. Documentation of the IRB’s review and approval of the request is also required 
by the HIPAA Privacy Rule. In fact, what kind of PHI access has been approved by IRB is 
essential to achieve automated access control in secondary-use datasets, an important long-term 
goal of our work.   
The Unanticipated Problem Report core defines the informational elements that should be 
reported to the IRB as well as the elements documenting the corresponding actions taken by the 
IRB. For this core, we adopted some concepts from the Adverse Event subdomain of the BRIDG 
model. Since adverse events are often required to be reported to other bodies such as a local Data 
and Safety Monitoring Committee, the sponsor, or the FDA, a standardized format can facilitate 
automated reporting and avoid duplicate report preparation efforts. 
The Application Amendment and Renewal core defines information entities such as amendment 
items and status report that are related to the IRB’s continuing review. A standardized status 
report can be automatically generated from existing information stored in a clinical trial 
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The Application Status core represents information related to the review status of an IRB 
application and can be shared with other CRI applications to automate a streamlined workflow. 
This can eliminate the needs for manually delivering paper-based IRB approval letters to 
different stakeholders in the research domain. 
The Ancillary Applications core covers areas such as radiation safety review committees, 
scientific review committees, conflict of interest committees, data and safety monitoring 
committees, etc., are also submitted to oversight committees in addition to the IRB, and many 
IRBs require ancillary application approvals before providing the final IRB approval. These 
ancillary oversight committees may or may not require extra information besides the standard 
IRB application. The IRB model presented is not intended to include the details of ancillary 
applications since many of them are dictated by local policies. However, the model is designed 
to be able to support any extension by local IRBs.  
Finally, the Regulatory applications core covers those application types mandated by regulatory 
authorities such as the FDA. For studies involving investigational drugs or significant risk 
devices, regulatory applications such as investigational new drug (IND) or investigational device 
exemption (IDE) are required to be reviewed and approved by the FDA, in addition to being 
approved by the IRB. The model is designed to support such requirement by defining 
constraining relationships between an IRB application and regulatory applications. 
 2.2.2.2 Terminology binding 
One of our major goals in developing the IRB DAM is to achieve interoperability between eIRB 
systems and other CRI systems. Implementation of the IRB entity-relationship model enables 
syntactic interoperability by specifying the structure of information being exchanged between 
different systems. However, to make the meaning of the exchanged content understandable to the 
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the HL7 data type CD (ConceptDescriptor) in the IRB entity-relationship model should be 
bound to value sets where each value set consists of one or more coded concepts. Such value sets 
can be defined from scratch or by adopting existing terminologies, code systems, or ontologies if 
available. For example, many “study characteristic” related value sets defined in OCRe such as 
“phase,” “blinding type,” and “sampling method” can be bound to the corresponding attributes in 
our IRB model.  Furthermore, certain consent related attributes can be bound to terms defined in 
existing research permission or informed consent ontologies [30,31] . We defined the value sets 
for a few attributes in the model as a preliminary IRB domain vocabulary specification effort and 
provide examples in Table 1.  
We are specifically focused on defining the values sets for attributes concerning data-access 
requests such asdataCategory and dataElementName (as shown in Figure 6). The value sets are 
represented by the Research-Oriented Health Data Representation (ROHDR) model  to define 
standardized representations of health data categories and specific data elements requested 
byresearchers. ROHDR is adapted from Common Data Model (CDM) Version 4 from the 
Observational Medical Outcomes Partnership (OMOP) [32] and can be accessed online at 
http://irb-dam.bmi.utah.edu/rohdr.A formal and comprehensive IRB domain vocabulary 
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Table 1. Example value sets for concept descriptors described by 
the Entity-relationship model. 
Example  IRB Application 
Status Value Set 
Example IRB Vulnerable 
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 Figure 6. Data-Access Request Related Classes in the IRB Model: the dataCategory 
and dataElementName attribute from the DataElement class will be bound to the 
ROHDR model to achieve semantic interoperability. 
 
2.2.2.3 The Business Process Model 
As illustrated in Figure 1, the behavioral business process model specifies the high-level features 
of the eIRB system. It focuses on the end-user’s perspective of the functionality of the 
application. Considering the potential variability in review workflows among different IRBs, the 
current business process model detailed on the Website below intentionally avoids detailed 
workflow design such as application review assignment, internal review processes, or meeting 
scheduling. The system interactions with investigators and IRB reviewers that we show in our 
business process model are generic enough, in our opinion, to be applicable across institutions. 
We expect that the model would be refined once others gain real-world experience with it. These 
models can be accessed online at http://irb-dam.bmi.utah.edu. 
2.3 Interaction Architecture Modeling 
The final phase of modeling, the interaction architecture model design, specifies interactions and 
information exchange between an eIRB system and other CRI systems to realize new features 
that are not supported by isolated systems. The interaction model is represented using the 
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Business Process Modeling Language (BPML) that is intended to provide a notation readily 
understandable by all stakeholders [33]. The BPMN Collaboration Diagram is one of the three 
sub-models supported by BPMN and is the most suitable for describing the interactions between 
different systems (participants) using Pools and message exchange between the participants 
using Message Flows. Example interactions can be found online. For example, the BPMN 2.0 
Models/IRB-Based Access Control for SUHD
2
 systems example illustrates an interaction model 
for automatically connecting an eIRB to a local external source of clinical data (protected health 
information). 
3. Model Evaluation 
The structural IRB entity-relationship model was evaluated to validate its support for 
representing informational elements found in diverse types of IRB applications at different 
institutions. The evaluation included comparisons with real-world IRB application systems from 
five representative institutions. These IRB application systems were chosen because they come 
from institutions across the nation and each of them is representative of a typical submission 
method or review setting. Table 2 summarizes the five IRB application systems used in the 
evaluation. 
3.1 Evaluation Methods  
The evaluation was performed from January to March 2013. The most up-to-date Web forms or 
Word/PDF application templates during that period of time at each institution were used for the 
evaluation. Each field defined in the Web form or Word/PDF templates was extracted as an 
information item and mapped to the IRB entity-relationship model (referred to as “Model”) with 
one of the eight mapping types as the mapping results described in Table 3. 
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Table 2. Summary of the Five IRB Application Systems 
IRB 
System 
System Type Review Setting 
A Locally customized commercial eIRB Academic Medical Center 
B In-house developed eIRB Academic Medical Center 
C Word templates submitted via e-mail or hard 
copy 
Academic Medical Center 
D Ad hoc eIRB Independent Commercial 
IRB 
E Mixed submission method combining e-mail 
and Software as a Service (Saas) eIRB 
Federal Centralized IRB 
 
The number of application forms and the content design of each form vary across the five 
organizations. Some of the variations are related to the differences in review model and review 
scope of each IRB. Example form types include initial application form and continuing review 
application form for health sciences or for social and behavioral sciences. Most organizations 
also require additional application forms for requesting IRB exemption and for studies involving 
medical devices, specimens, data repositories, or vulnerable populations. Crossover fields in 
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A 280 23.9% 14.3% 17.1% 21.1% 5.4% 7.5% 9.6% 1.1% 
B 241 14.9% 20.7% 35.7% 7.5% 6.6% 4.9% 8.7% 0.8% 
C 263 20.5% 23.6% 16.3% 10.6% 9.1% 2.7% 13.7% 3.4% 
D 302 13.6% 8.3% 32.5% 18.2% 2.6% 14.9% 9.6% 0.3% 
E 141 17.7% 6.4% 21.3% 22.7% 2.8% 16.3% 12.1% 0.7% 
1 
Exact mapping:  the form field can be exactly mapped to an attribute of a class in the Model. 
2 
Equivalent mapping:  the form field can be semantically equal-mapped to the Model by combining more than one attributes from 
one or more classes. 
3 
Partial mapping:  the Model has a general attribute covering more than one related form fields but lacks the specificity defined in 
the form fields. 
4 
Supportable mapping:  the form field is supported by defining value set(s) for a certain attribute in the Model. 
 5





Out of scope: the form field is defined according to local regulations or policies and it is intentionally excluded from the core 
model. However, it is possible to extend the Model to support such local policies. 
7 
Not defined: the Model does not have a corresponding class or attribute defined for the form field. 
8 
Unclear: the definition of the form field is not clear. 
3.2 Evaluation Results 
The evaluation results produced granular and complicated mapping categories but 
showed overall agreement between these real systems and our model. As shown in Table 
3, about 10-15% of items defined by the IRB organizations are not covered in the Model. 
These undefined items reflect elements that are not covered by the current knowledge 
sources used for developing the Model but are worth considering due to the important 
role they play in human subject protection. During the mapping analysis, several areas 
such as humanitarian use device and use of radioactive drugs were identified that are 
regulated in federal laws but that are not included in AAHRPP guidelines. Therefore, 
corresponding classes and attributes in these areas were added to the Model after the 
mapping analysis. There are also undefined form fields in the Model that are based on 
best practices. For example, some IRBs ask for extra details for placebo-controlled 
studies. Federal regulations do not address this specific type of study but some IRBs 
require more information due to potential risks posed by this type of study. A collection 
of such specializations is valuable because it can inform best practices in the IRB 
domain.  
The model evaluation process revealed limitations of the IRB DAM in representing certain 
aspects of real-world IRB applications, especially in defining information elements about 
subjective evaluations and justifications from investigators for a certain study activity, or 
foreseen events that can be fully expressed only with free text. This limitation is caused by the 
nature of information models whose strength lies in representing discrete and machine-
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4. Discussion 
Although our prototype implementation of an IRB DAM showed decent coverage across several 
IRB types, a formal evaluation of performance improvement and user satisfaction when the 
model is used as part of a eIRB-CRI  integrated workflow is needed to make the proposed 
solution more convincing. The development of the IRB DAM was initially motivated by 
addressing the need to integrate a local CRI data query system and an eIRB system to realize 
automated access control of PHI based on IRB approval.[34] However, the value of the IRB 
DAM extends beyond this use case. With a standard IRB model, an eIRB system can in theory 
be integrated with any CRI system (e.g., clinical trial management systems, electronic data 
capture systems, clinical trial registries, other eIRBs, etc.) to streamline the clinical research 
workflow, which will be part of our future work to demonstrate the utility of the IRB model. 
The author who developed the model performed the evaluation of the model, which may cause 
some mapping biases. However, the actual value of the evaluation does not lie in the specific 
numbers listed in the mapping result (Table 3). As demonstrated by the complicated mapping 
results, the purpose of the evaluation is not to categorize the model simply as “good” or “bad.” 
There is no gold standard regarding to the design of IRB application forms. The five IRB 
application systems chosen in the evaluation phase are representative, but this does not mean 
their application forms are perfect. The comparison between the IRB model and the real-world 
IRB application forms identified several important insights about the model: 
 The model has covered the core information elements required by representative IRBs, as 
shown by the small percentage of the Not Defined mapping category;  
 For fields not covered in the model, some belong to local context and should not be included 
in the core model, and some may be potentially considered in the future version of the model 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
 Items that are currently free text can be defined in a structured format according to the model 
as indicated by the Equivalent mapping category;  
 There are ambiguous fields in the current IRB application forms that should be clarified, as 
indicated by the Unclear mapping category;  
 The evaluation process identified valuable sources for future development of the domain 
vocabulary for the Model since many Supportable Mapping fields suggest the possible values 
for a certain attribute in the Model.  
In short, the evaluation provided insight with regard to future improvement to both the IRB 
model development and real-world IRB application form design. 
Like any modeling effort, developing an IRB DAM that meets real-world application 
requirements needs many rounds of iteration and revision. As future work, we envisage 
continuing iterative development of the model by collaborating with more IRB domain experts 
and clinical researchers. A formal evaluation of the expressiveness of the data request related 
classes needs to be performed, possibly by annotating previously submitted IRB applications. 
We plan to promote the adoption of the IRB model by collaborating with other CTSA centers 
that have eIRBs. At the same time, we plan to integrate the IRB DAM with the BRIDG model 
through a harmonization process developed by BRIDG.  
Structured and computable IRB application information could provide the foundation for 
automated review decision support with predefined rules, thus enhancing review quality and 
efficiency. We plan to develop more advanced applications of the IRB model such as facilitated 
computer decision support for IRB reviewers in our institutional eIRB system. For example, 
applications could be automatically assigned to IRB members with corresponding experience or 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
activities involve high-risk procedures such as ionizing radiation, or informational risks such as 
secondary use of existing data or specimens, commensurate review procedures for risk can be 
suggested by the system. This could help IRBs allocate their limited resources to ensure human 
subject protection while enabling responsible research to proceed. 
5. Conclusion 
This paper focuses on the technical aspect of the issues in the IRB oversight domain. We 
described the development and evaluation process of the IRB DAM in detail. We demonstrated 
that the IRB model is broadly representative across a variety of IRB types. This paper fills a gap 
in standardization and modeling efforts in the clinical research informatics domain of IRB 
oversight and support. 
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